IJC Heart & Vasculature 31 (2020) 100676

Contents lists available at ScienceDirect

IJC Heart & Vasculature

journal homepage: www.journals.elsevier.com/ijc-heart-and-vasculature

Erratum

Erratum regarding missing Declaration of Competing Interest statements in previously published articles



Declaration of Competing Interest statements were not included in the published version of the following articles that appeared in previous issues of IJC Heart & Vasculature

The appropriate Declaration/Competing Interest statements, provided by the Authors, are included below.

1. Impairment of left atrial function and cryptogenic stroke: Potential insights in the pathophysiology of stroke in the young [IJC Heart & Vasculature 26 (2020) 100454] https://doi.org/10.1016/j.ijcha.2019.100454

Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

2. Low-frequency and low-intensity ultrasound increases cardiac parasympathetic neural activity and decreases clinic hypertension in elderly hypertensive subjects with type 2 diabetes [IJC Heart & Vasculature 19 (2018) 34–36] https://doi.org/10.1016/j.ijcha.2018.04.002

Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

3. The sternal wire code; Solving the problem of missing coronary artery bypass graft records during cardiac catheterization [IJC Heart & Vasculature 19 (2018) 37–40] https://doi. org/10.1016/j.ijcha.2018.04.004

Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

 Hypertrophic cardiomyopathy [IJC Heart & Vasculature 27 (2020) 100503] https://doi.org/10.1016/j.ijcha.2020.100503

Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

- analysis including 22,500 patients from 14 studies [IJC Heart & Vasculature 22 (2019) 39–45] https://doi.org/10.1016/j. ijcha.2018.11.008
 Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
 - Reverse remodeling in Dilated Cardiomyopathy: Insights and future perspectives [IJC Heart & Vasculature 18 (2018) 52–57] https://doi.org/10.1016/j.ijcha.2018.02.005

5. Short term outcome following acute phase switch among

P2Y12 inhibitors in patients presenting with acute coronary

syndrome treated with PCI: A systematic review and meta-

Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

 Mobilization of progenitor cells and assessment of vessel healing after second generation drug-eluting stenting by optical coherence tomography [IJC Heart & Vasculature 18 (2018) 17–24] https://doi.org/10.1016/j.ijcha.2017.12.003

Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

 Trimethylamine N-oxide in atrial fibrillation progression [IJC Heart & Vasculature 29 (2020) 100554] https://doi.org/10. 1016/j.ijcha.2020.100554

Declaration of competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

 Computed tomography guided sizing for transcatheter pulmonary valve replacement [IJC Heart & Vasculature 29 (2020) 100523] https://doi.org/10.1016/j.ijcha.2020.100523

Declaration of competing interest: Dr Vaikom S Mahadevan is a principle investigator for pulmonic valve clinical trials for Edwards Life Sciences. No conflicts of interests for any of the other authors.

 Does combination therapy work in chronic thromboembolic pulmonary hypertension? [IJC Heart & Vasculature 29 (2020) 100544] https://doi.org/10.1016/j.ijcha.2020.100544

Declaration of competing interest: M. van Thor, J. Mager and M. Post report grants from Actelion Pharmaceuticals. J. Kelder

DOI of original articles: https://doi.org/10.1016/j.ijcha.2018.04.002, https://doi.org/ 10.1016/j.ijcha.2018.04.004, https://doi.org/10.1016/j.ijcha.2019.100454, https://doi. org/10.1016/j.ijcha.2018.11.008, https://doi.org/10.1016/j.ijcha.2020.100554, https:// doi.org/10.1016/j.ijcha.2018.02.005, https://doi.org/10.1016/j.ijcha.2020.100503, https://doi.org/10.1016/j.ijcha.2020.100523, https://doi.org/10.1016/j.ijcha.2020. 100502, https://doi.org/10.1016/j.ijcha.2019.100398, https://doi.org/10.1016/j.ijcha. 2017.12.003, https://doi.org/10.1016/j.ijcha.2020.100544

has nothing to disclose. R. Snijder reports grants from Pfizer and Actelion Pharmaceuticals.

11. Vernakalant and electrical cardioversion for AF – Safe and effective [IJC Heart & Vasculature 24 (2019) 100398] https://doi.org/10.1016/j.ijcha.2019.100398

Declaration of competing interest: No study specific funding was obtained; however some patients simultaneously participated in an ongoing post approval safety study (SPECTRUM) sponsored by Cardiome Pharma Corp. or were included in a RCT receiving limited grants by the Jubilaeumsfonds of the Austrian National Bank.

 Not typical angina and mortality in women with obstructive coronary artery disease: Results from the Women's Ischemic Syndrome Evaluation study (WISE) [IJC Heart & Vasculature 27 (2020) 100502] https://doi.org/10.1016/j.ijcha.2020. 100502

Declaration of competing interest: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: I, Dr. C. Noel Bairey Merz, serve as Board of Director for iRhythm, fees paid through CSMC from Abbott Diagnostics and Sanofi.